Pipeline

January 10, 2020

Company	Drug/Device	Medical Condition	Status
X4 Pharmaceuticals	Mavorixafor in Combination with Ibrutinib	Waldenström’s macroglobulinemia	phase 1b clinical trial initiated, enrolling 12 to 18 patients
Sol-Gel Technologies	SGT-210	punctate palmoplantar keratoderma type -1	phase 1 proof-of-concept study initiated, enrolling 15 patients
BioXcel Therapeutics	BXCL501 (dexmedetomidine)	agitation associated with dementia	phase 1b/2 initiated, enrolling first patient
Agenus	AGEN1223	cancer	phase 1 trial initiated, dosing first patient
InhibRX	INBRX-106	solid tumors	phase 1 trial initiated, dosing first patient
Locus Biosciences	LBP-EC01	e. coli bacteria causing urinary tract infections	phase 1b trial opened for enrollment
Gemini Therapeutics	GEM103	dry age-related macular degeneration	phase 1 trial initiated, enrolling 9 patients
Cytokinetics	CK-3773274 (CK-274)	hypertrophic cardiomyopathy	phase 2 trial opened to enrollment
Protagonist Therapeutics	hepcidin mimetic PTG-300	hereditary hemochromatosis	phase 2 initiated
CStone Pharmaceuticals Blueprint Medicines	fisogatinib in combination with CS1001	locally advanced or metastatic hepatocellular carcinoma	phase 1b/2 trial’s dosing of first patient
Opthea	OPT-302 administered in combination with aflibercept (Eylea®)	diabetic macular edema	phase 2a trial patient recruitment completed for 108 patients
Galera Therapeutics	avasopasem manganese (GC4419)	radiation-induced esophagitis in patients with lung cancer	phase 2a trial first patient dosed, enrolling 60 patients
TLC	TLC590	pain management	part 2 of a phase 2 trial dosing first patient of 150 patients
PellePharm	patidegib topical gel, 2%,	non-Gorlin High Frequency Basal Cell Carcinoma	phase 2 trial dosing first 2 patients of 40 patients
Promethera Biosciences	HepaStem	acute-on-chronic liver failure	phase 2b trial initiated, enrolling 363 patients
Zai Lab Novocure	Tumor Treating Fields in combination with chemotherapy	gastric adenocarcinoma	phase 2 trial, first patient enrolled of 50 patients
SELLAS Life Sciences Group	galinpepimut-S	acute myeloid leukemia	phase 3 trial enrolling 116 patients across approximately 50 clinical sites in the U.S. and Europe
BioXcel Therapeutics	BXCL501 (dexmedetomidine)	agitation associated with schizophrenia and bipolar disorder	phase 3 trial enrolling up to 750 patients 18 to 75 years of age
Clover Biopharmaceuticals	SCB-808 (etanercept biosimilar)	ankylosing spondylitis	phase 3 trial enrolling patients at multiple sites in China
Eli Lilly	LOXO-292 (selpercatinib)	RET-mutant medullary thyroid cancer	phase 3 trial enrolling 400 patients
Mallinckrodt Pharmaceuticals	Acthar Gel (repository corticotropin injection)	severe keratitis	phase 4 trial enrolling 30 patients
Reflow Medical	Temporary Spur Stent System	below-the-knee peripheral artery disease	Breakthrough Device designation granted by the FDA
Savara	Molgradex	autoimmune pulmonary alveolar proteinosis	Breakthrough Therapy designation granted by the FDA
Advaxis	ADXS-504	prostate cancer	IND approval granted by the FDA
OncoImmune	ONC-392	non-small cell lung cancer	IND approval granted by the FDA
Colospan	CG-100 temporary intraluminal bypass device	anastomotic leaks in patients undergoing colorectal surgery	IDE granted by the FDA
Merck	Keytruda (pembrolizumab)	Bacillus Calmette-Guerin -unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ	Approved by the FDA
Blueprint Medicines	AYVAKIT (avapritinib)	unresectable or metastatic gastrointestinal stromal tumor	Approved by the FDA
Novo Nordisk	Fiasp (insulin aspart injection)	pediatric diabetes	New indication approved by the FDA
AstraZeneca Merck	Lynparza (olaparib)	pancreatic cancer	Approved by the FDA
Myriad Genetics	BRACAnalysis CDx	metastatic pancreatic cancer with a germline BRCA mutation	Approved by the FDA